Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide*
Lido
7256
Vezesque se leu este artigo
3231
Total PDF
4025
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 172 | 121 | 293 |
| 2025 9 | 164 | 93 | 257 |
| 2025 8 | 128 | 62 | 190 |
| 2025 7 | 159 | 66 | 225 |
| 2025 6 | 131 | 59 | 190 |
| 2025 5 | 137 | 74 | 211 |
| 2025 4 | 131 | 46 | 177 |
| 2025 3 | 170 | 61 | 231 |
| 2025 2 | 122 | 78 | 200 |
| 2025 1 | 108 | 49 | 157 |
| 2024 12 | 105 | 56 | 161 |
| 2024 11 | 90 | 46 | 136 |
| 2024 10 | 81 | 66 | 147 |
| 2024 9 | 88 | 75 | 163 |
| 2024 8 | 112 | 112 | 224 |
| 2024 7 | 130 | 107 | 237 |
| 2024 6 | 104 | 74 | 178 |
| 2024 5 | 126 | 62 | 188 |
| 2024 4 | 88 | 82 | 170 |
| 2024 3 | 69 | 71 | 140 |
| 2024 2 | 86 | 80 | 166 |
| 2024 1 | 52 | 47 | 99 |
| 2023 12 | 48 | 51 | 99 |
| 2023 11 | 63 | 72 | 135 |
| 2023 10 | 45 | 73 | 118 |
| 2023 9 | 52 | 53 | 105 |
| 2023 8 | 43 | 35 | 78 |
| 2023 7 | 49 | 33 | 82 |
| 2023 6 | 56 | 32 | 88 |
| 2023 5 | 52 | 23 | 75 |
| 2023 4 | 44 | 22 | 66 |
| 2023 3 | 47 | 35 | 82 |
| 2023 2 | 38 | 33 | 71 |
| 2023 1 | 39 | 31 | 70 |
| 2022 12 | 34 | 20 | 54 |
| 2022 11 | 55 | 40 | 95 |
| 2022 10 | 44 | 26 | 70 |
| 2022 9 | 46 | 62 | 108 |
| 2022 8 | 37 | 35 | 72 |
| 2022 7 | 28 | 38 | 66 |
| 2022 6 | 42 | 45 | 87 |
| 2022 5 | 23 | 44 | 67 |
| 2022 4 | 29 | 42 | 71 |
| 2022 3 | 39 | 52 | 91 |
| 2022 2 | 20 | 29 | 49 |
| 2021 1 | 29 | 51 | 80 |
| 2021 12 | 38 | 43 | 81 |
| 2021 11 | 45 | 63 | 108 |
| 2021 10 | 56 | 63 | 119 |
| 2021 9 | 34 | 51 | 85 |
| 2021 8 | 30 | 46 | 76 |
| 2021 7 | 33 | 43 | 76 |
| 2021 6 | 34 | 55 | 89 |
| 2021 5 | 37 | 39 | 76 |
| 2021 4 | 95 | 201 | 296 |
| 2021 3 | 26 | 34 | 60 |
| 2021 2 | 18 | 13 | 31 |
| 2020 1 | 17 | 12 | 29 |
| 2020 12 | 7 | 4 | 11 |
Mostrar tudo
